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Summary
Background Dopamine is a key modulator of striatal function and learning and might improve motor recovery after 
stroke. Previous small trials of dopamine agonists after stroke provide equivocal evidence of effectiveness on 
improving motor recovery. We aimed to assess the safety and efficacy of co-careldopa plus routine occupational 
and physical therapy during early rehabilitation after stroke. 
Methods This double-blind, multicentre, randomised controlled trial of co-careldopa versus placebo in addition to 
routine NHS occupational and physical therapy was done at 51 UK NHS acute inpatient stroke rehabilitation 
services. We recruited patients with new or recurrent clinically diagnosed ischaemic or haemorrhagic (excluding 
subarachnoid haemorrhage) stroke 5–42 days before randomisation, who were unable to walk 10 m or more, had a 
score of less than 7 points on the Rivermead Mobility Index, were expected to need rehabilitation, and were able to 
access rehabilitation after discharge from hospital. Participants were assigned (1:1) using stratified random blocks to 
receive 6 weeks of oral co-careldopa or matched placebo in addition to routine NHS physiotherapy and occupational 
therapy. The initial two doses of co-careldopa were 62·5 mg (50 mg of levodopa and 12·5 mg of carbidopa) and the 
remaining doses were 125 mg (100 mg of levodopa and 25 mg of carbidopa). Participants were required to take a 
single oral tablet 45–60 min before physiotherapy or occupational therapy session. The primary outcome was ability 
to walk independently, defined as a Rivermead Mobility Index score of 7 or more, at 8 weeks. Primary and safety 
analyses were done in the intention-to-treat population. The trial is registered on the ISRCTN registry, number 
ISRCTN99643613.
Findings Between May 30, 2011, and March 28, 2014, of 1574 patients found eligible, 593 (mean age 68·5 years) were 
randomly assigned to either the co-careldopa group (n=308) or to the placebo group (n=285), on an average 18 days 
after stroke onset. Primary outcome data were available for all 593 patients. We found no evidence that the ability to 
walk independently improved with co-careldopa (125 [41%] of 308 patients) compared with placebo (127 [45%] of 
285 patients; odds ratio 0·78 [95% CI 0·53–1·15]) at 8 weeks. Mortality at 12 months did not differ between the two 
groups (22 [7%] vs 17 [6%]). Serious adverse events were largely similar between groups. Vomiting during therapy 
sessions, after taking the study drug, was the most frequent adverse event and was more frequent in the co-careldopa 
group than the placebo group (19 [6·2%] vs 9 [3·2%]).
Interpretation Co-careldopa in addition to routine occupational and physical therapy does not seem to improve 
walking after stroke. Further research might identify subgroups of patients with stroke who could benefit from 
dopaminergic therapy at different doses or times after stroke with more intensive motor therapy.
Funding Medical Research Council.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Studies of the brain structures involved in learning suggest 
that the basal ganglia and dopamine play a key part in the 
acquisition of motor skills. Dopamine is a key modulator 
of striatal function and might contribute to motor recovery 
after stroke.1,2 Preclinical studies3,4 suggest that the potential 
mechanisms of action of dopamine in improving motor 
learning are through potentiating drive and arousal in 
conditioned learning and up-regulation of glutaminergic 
transmission, which modulates synaptic efficacy. Levodopa 
is an orally-administered dopamine pre cursor that crosses 
the blood–brain barrier before being metabolised to 
dopamine. Co-careldopa is an established treatment for 
Parkinson’s disease that combines levodopa with carbi-
dopa, a peripheral DOPA-decarboxylase inhibitor that 
maximises the central bioavailability of levodopa.
One systematic review5 of clinical trials investigated the 
use of dopamine agonists to enhance motor recovery from 
stroke and concluded that the evidence was insufficient. 
Seven small trials of dopamine agonists after stroke have 
provided equivocal evidence on motor recovery.6–12 Trials 
were of variable quality, with small sample sizes,8,10 short 
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follow-up,10 single doses of co-careldopa,10 and recruitment 
of patients months or years after stroke.8,10 Four of the 
seven trials showed improvement in a motor outcome.6,8,9,12 
Therefore, a larger, random ised controlled trial is needed 
to investigate whether levodopa enhances recovery from 
stroke.
To optimise efficacy of dopaminergic therapy and 
minimise adverse effects, administering levodopa before 
motor therapy to enhance brain dopamine concentra-
tions during therapy is a logical strategy. We hypothes-
ised that elevating central dopaminergic activity during 
motor therapy early after stroke onset would improve 
motor recovery, when the potential for recovery might 
be greater.
The DARS trial aims to assess whether giving a com-
bination of co-careldopa for up to 6 weeks with routine 
occupational and physical therapy during early rehabilita-
tion after stroke enhances the effect of conven tional re-
hab ilitation on the ability to walk independently for 10 m 
or more.13
Methods
Study design and participants
DARS was a multicentre, prospective, double-blind, 
randomised placebo-controlled trial of NHS physical 
therapy and occupational therapy treatment alone versus 
NHS physical therapy and occupational therapy with up 
to 6 weeks co-careldopa treatment for people with new or 
recurrent stroke admitted to acute stroke services in 
hospital. Recruitment was from 51 UK NHS acute 
inpatient stroke rehabilitation services with a community 
stroke rehabilitation service.
Eligible participants had new or recurrent clinically 
diagnosed ischaemic or haemorrhagic stroke 5–42 days 
before randomisation, could not walk independently for 
10 m or more indoors, had a Rivermead Mobility Index 
(RMI; a 15-item scale that assesses functional mobility in 
gait, balance, and transfers after stroke)14 score of less than 
7 (marked by a health-care professional), and were able 
to give written informed consent, access rehab ilitation 
treatment within 5 days of hospital dis charge, and were 
expected to be in hospital for adminis tration of at least 
their first two trial medication doses. Exclusion criteria 
included diagnosis of Parkinson’s disease or symptomatic 
orthostatic hypotension (panel). De tailed trial methods are 
described elsewhere13 and can be found in the trial protocol 
(appendix). Ethical approval was obtained through the UK 
National Research Ethics Service (10/H1005/6).
Randomisation and masking
Participants were randomly assigned (1:1) via a computer-
generated programme, with the use of ran dom permu-
tated blocks of size four, to receive either co-careldopa or 
placebo. Stratification factors were centre, type of stroke 
(primary intracranial haemorrhage or in farct), and RMI 
score (0–3 or 4–7). Patients, clinicians, re searchers, and 
Research in context
Evidence before this study
We did a systematic search of MEDLINE (1946–Sept 25, 2015), 
Embase (1996–Week 42, 2014), Embase Classic 
(1947–Sept 25, 2015), PsychINFO (1806–Sept 25, 2015), and 
the Cochrane Database of Systematic Reviews for randomised 
controlled trials and systematic reviews assessing 
dopaminergic therapy on motor recovery after stroke. The 
search included expanded terms relating to “stroke”, 
“dopamine”, and “rehabilitation” (appendix). Only one 
systematic review had examined the use of dopamine agonists 
to enhance motor recovery from stroke in humans. 
Two studies concerning the use of levodopa met the review 
inclusion criteria, neither of which showed evidence of a 
positive treatment effect with this drug. Seven other trials, not 
cited by the systematic review, addressed this question. These 
trials were of variable quality and reported mixed results. 
Many were limited by small sample sizes (n=10–100) or 
comparatively short follow-ups (15–180 days), or only single 
doses of co-careldopa were administered. Some recruited 
patients months or years after stroke. Several trials showed 
benefits of dopamine on motor outcomes; however, others 
found no improvement. These disparate findings have not 
thus far addressed the question whether pharmacological 
manipulation of the dopaminergic systems could be used to 
enhance the reacquisition of motor skills after stroke.
Added value of the study
We found no evidence that combining dopaminergic therapy 
with routine NHS occupational and physical therapy was 
effective in improving walking after stroke. Our study was 
limited by the 10% of patients who were lost to follow-up at 
8 weeks; less than 10% of patients met the strict definition to 
be included in per-protocol analysis of the primary outcome; 
and the intensity of therapy delivered in DARS could have been 
insufficient. Despite these limitations, the findings seem to be 
robust and generalisable to patients with limited mobility in 
the first few weeks after stroke.
Implications of all the available evidence
The findings of our study appear consistent with smaller studies 
of dopaminergic therapy. A formal meta-analysis of trials of 
dopaminergic therapy in stroke recovery has not been done and 
given the wide range of different outcome measures in 
populations of patients with stroke recruited at different times 
after stroke, it might not be justified. Further research is needed 
to develop imaging and clinical markers that will allow 
identification of promising drug therapies that might enhance 
motor therapy for improving walking ability and arm function 
after stroke. Subgroups of patients with stroke who might benefit 
from dopaminergic therapy at different doses or times after 
stroke with more intensive motor therapy need to be identified.
See Online for appendix
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trial staff were masked to treatment allo cation, which was 
continued throughout the trial period and follow up. 
Potential participants were identified by National Institute 
for Health Research Stroke Research Network (SRN) staff 
in liaison with ward nurses and therapists. 
Procedures
Participants received either co-careldopa (Sinemet) or 
matching placebo before routine therapy sessions, for a 
maximum of 6 weeks. The content and number of 
sessions was variable according to patient need and was 
decided as part of the routine management of the patient. 
The initial two co-careldopa doses were both 62·5 mg 
(levodopa 50 mg; carbidopa 12·5 mg) and subsequent 
doses were 125 mg (levodopa 100 mg; carbidopa 25 mg). 
Participants took the study drug orally 45–60 min before 
physical therapy or occupational therapy sessions directed 
at motor skills (walking, transfers, dressing). Therapy 
staff recorded details of every therapy session delivered 
from day of randomis ation to the last administration of 
co-careldopa or placebo or 6 weeks post-randomisation 
(whichever was sooner). This included timing of drug 
administration in relation to therapy, duration of therapy 
session (overall and by activity), and role of therapist 
present. Patients might not have been able to take the 
drug 45–60 min before the start of a therapy session. In 
these situa tions, the drug was administered immediately 
before the start of a session. 
Baseline data were collected by the clinical research 
team from clinical records and via face-to-face adminis-
tration of the questionnaires. All baseline data were 
collected before randomisation. Follow-up data and 
safety data were collected at 8 weeks, 6 months, and 
12 months, face-to-face, in the participant’s home, at the 
hospital, or at a community facility. Data were recorded 
on paper case report forms provided by the Clinical Trials 
Research Unit. Completion of the primary outcome 
measure (RMI) was via telephone when it was not 
possible to arrange a face-to-face visit.
Outcomes
The primary outcome was the ability to walk at least 10 m 
independently at 8 weeks after randomisation, as mea-
sured by an RMI score or 7 or more and positive response 
to item 7 (walk at least 10 m independently with an aid if 
necessary, but no standby help).
Secondary outcomes were independent walking at 
6 months and 12 months (RMI score ≥7), physical func-
tioning (Nottingham Extended Activities Daily Living 
[NEADL],15, Barthel Index,16 ABILHAND Manual Ability 
Measure,17 modified Rankin Scale [mRS]),18 cost-effective-
ness, pain (musculoskeletal symptoms and signs and 
pain [MSK-SSP] Manikin), cognition (Montreal Cognitive 
Assess ment),19 mood (General Health Questionnaire 12 
[GHQ-12]),20 fatigue (Fatigue Assessment Scale),21 and 
carer burden (Caregiver Burden Scale [CBS])22 at 8 weeks, 
6 months, and 12 months.
Follow-up and safety data were collected face-to-face, 
where possible, by an independent, masked researcher. 
RMI assessment was completed via telephone if a face-
to-face visit was not possible. Adverse events were 
collected until the 8-week follow up appointment. All 
serious adverse events were collected up to 30 days after 
the last dose of protocol treatment.
Statistical analysis
Based on a previous study,12 572 participants would pro-
vide 90% power at 5% significance to detect a 50% relative 
difference (13% absolute difference) between placebo 
and active treatment groups in the primary out come, 
assuming that 26% of people in the placebo group 
Panel: Inclusion and exclusion criteria 
Inclusion criteria:
• New or recurrent clinically diagnosed ischaemic or 
haemorrhagic (excluding subarachnoid haemorrhage) 
stroke within 5–42 days before randomisation
• Cannot walk 10 m or more indoors independently 
(ie, without use of physical assistance)
• Achieved a score of less than 7 points on the Rivermead 
Mobility Index, scored by a professional
• Expected to need rehabilitation treatment
• Aged 18 years and older
• Able to give informed consent
• Able to access continuity of rehabilitation treatment after 
discharge from hospital (ie, continuity of rehabilitation 
available within 5 days after discharge)
• Expected to be able to comply with the treatment 
schedule
• Expected to be in hospital for at least their first two doses 
of trial medication
Exclusion criteria:
• Not expected to survive for 2 months after stroke
• A diagnosis of Parkinson’s disease, severe medical or 
surgical illness, or severe psychosis
• Known hypersensitivity or contraindications to 
co-careldopa
• Symptomatic orthostatic hypotension
• Required physical assistance from at least one person to 
walk before stroke due to pre-existing comorbidities 
(eg, heart failure or osteoarthritis)
• Pregnancy, lactation, or, in the case of women of 
child-bearing potential, unwillingness to use 
medically-approved contraception during treatment and 
for 1 month after treatment had finished
• Participation in another interventional drug or treatment 
therapy trial
• Inability to walk 10 metres or further indoors before 
stroke (with a walking aid if necessary, but without 
physical assistance, which, in this context, means help 
from one or more people)
Articles
www.thelancet.com/neurology   Vol 18   June 2019 533
Figure: Trial profile
*Categories are not mutually 
exclusive —ie, some patients 
had more than one exclusion 
criteria. †Initial screening 
categories. 
19 509 participants screened
17 962 ineligible*
    8445 can walk ≥10 m indoors independently
 2404 unable to consent
 1426 no continuity of rehabilitation therapy
 1362 could not walk pre-stroke
 1151 survival <2 months expected
 1093 other comorbidity
 1044 cannot swallow tablets or capsules
 989 not stroke
 361 not new stroke†
 551 rehabilitation not required
 432 participating in another trial
    337 hypersensitivity or contraindications
 9 concurrent medications†
 6 pregnancy, lactation, contraception
 460 not completed or missing
1547 eligible
948 did not consent*
 495 patient refused
 216 patient discharged before consent
 187 patient died
 46 other
 7 not completed or missing
599 consented
6 not randomly assigned
 1 could not walk before stroke
 1 not new stroke†
 4 not completed
593 randomly assigned
285 assigned to placebo
24 lost to follow-up 
 1 died
 11 withdrew
 2 could not contact
 1 moved out of area
 2 too unwell
 1 outcome booklet lost at site
 2 refused to complete
 2 other
 2 unknown
285 analysed at 8 weeks for primary
 outcome (261 analysed at 
 8 weeks for secondary outcome)
35 lost to follow-up 
 7 died
 15 withdrew
 5 could not contact 
 4 moved out of area
 1 too unwell
 1 outcome booklet lost at site
 1 refused to complete
 1 unknown
250 analysed at 6 months
221 analysed at 12 months 
64 lost to follow-up 
 17 died
 22 withdrew
 12 could not contact
 5 moved out of area
 4 too unwell
 2 refused to complete
 1 unwilling for visit
 1 other
308 assigned to co-careldopa
37 lost to follow-up 
 6 died
 24 withdrew
 1 moved out of area
 1 too unwell
 4 outcome booklet lost at site
 1 other
308 analysed at 8 weeks for primary
 outcome (271 analysed at 
 8 weeks for secondary outcome)
66 lost to follow-up 
 13 died
 30 withdrew
 10 could not contact 
 4 moved out of area
 4 too unwell
 1 refused to complete
 1 unwilling for visit
 2 other
 1 uknown
242 analysed at 6 months
222 analysed at 12 months 
86 lost to follow-up 
 21 died
 42 withdrew
 15 could not contact
 5 moved out of area
 1 refused to complete
 2 other
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achieve independent walking at 8 weeks, allowing for 
5% mortality rate. Since trial monitoring indicated that 
the combined mortality rate and loss to follow-up was 
likely to exceed 10%, the sample size was increased to 
590–600 participants.
We based analyses on the intention-to-treat population 
(ITT), with significance assessed at the 5% level. We 
included all randomly assigned participants in the 
primary ITT analysis, assuming those participants who 
died or were lost to follow-up were unable to walk inde-
pendently. We used a multilevel logistic regression model, 
adjusting for stratification variables: age, sex, type of 
stroke, RMI baseline score, centre (fitted as a random 
effect), baseline prestroke NEADL and Barthel Index 
scores, and number of days from stroke to randomisation. 
We report parameter estimates or odds ratios (ORs), with 
95% CIs and p values (fixed effects) or SEs (random 
effects). Sensitivity analyses assessed the robustness of 
the primary analysis. We included all randomly assigned 
participants in the safety analyses.
We analysed independent walking ability at 6 months 
and 12 months after randomisation in a similar way. We 
used stepwise multilevel linear regression to analyse 
secondary endpoints, except for mRS, for which we used 
a stepwise multilevel proportional odds logistic regres-
sion model. We used further analyses to assess the 
sensitivity of the conclusions of this analysis to non-
compliance, using a staged definition based on whether 
and when the drug was taken, the amount of motor 
therapy, and the number of sessions.
We estimated the incremental cost per quality-adjusted 
life-year (QALY) from the UK health and social care 
perspective over 12 months using the within-trial eco-
nomic evaluation. We based costs on a resource use 
questionnaire and utility derived from the European 
Quality of Life–Five Dimensions Questionnaire (EQ-5D) 
measure. We used multiple imputation to handle missing 
data. Non-parametric bootstrapping characterised un-
certainty in the incremental cost-effectiveness ratio. All 
analyses were completed in SAS software, version 9.2.
Role of funding source
The funder of the study had no role in the study design, 
data collection, data analysis or data interpretation, or 
writing of the report. The corresponding author had ac-
cess to all the data in the study and had final responsibility 
for the decision to submit for publication.
Results
During recruitment from May 30, 2011, to March 28, 2014, 
of 1547 eligible individuals, 593 (38%) were randomly 
assigned: 308 to the co-careldopa group and 285 to the 
placebo group (figure). Baseline demographic character-
istics were balanced between the two groups (table 1).
In total, 532 (90%) participants completed follow-up 
assessments at 8 weeks, 492 (83%) at 6 months, and 
443 (75%) at 12 months (figure). Baseline characteristics 
of non-responders did not differ between groups at any 
timepoint, except at 6 months, when non-responders 
had higher prestroke NEADL scores in the co-careldopa 
group than in the placebo group (59·6 vs 52·5 points). 
During the trial, 14 551 motor therapy sessions were 
delivered (mean of 23·2 sessions [SD 14·4] per patient, 
and mean duration of 42·8 [15·1] min in the co-careldopa 
group; mean of 24·8 [12·5] sessions per patient, and 
mean duration of 43·1 [16·0] min in the placebo group). 
The average time spent on motor activities was 40 min 
[SD 15]. More participants in the placebo group than in 
the co-careldopa group received sufficient motor therapy 
(at least five therapy sessions and ≥20 min motor therapy 
in at least 80% therapy sessions; 257 [90%] of 285 patients 
vs 259 [84%] of 308 patients).
The study drug was taken per protocol (45–60 min 
before therapy) in 8006 (55%) of 14 451 therapy ses-
sions and either less than 45 min or more than 60 min 
before therapy in a further 3843 (26%) sessions (appendix). 
Participants in the co-careldopa group received a mean 
of 20·7 study drug doses (SD 13·1), and the placebo 
group 22·4 (11·1). 14 (2%) participants (ten in the co-
careldopa group and four in the placebo group) did not 
receive any study drug doses or therapy, mainly due 
to withdrawal before therapy.
The primary analysis did not provide evidence of a 
difference in the proportion of participants walking 
independently at 8 weeks (125 [41%] of 308 patients in the 
co-careldopa group vs 127 [45%] of 285 patients in the 
placebo group; OR 0·78 [95% CI 0·53–1·15]; table 2). 
Co-careldopa 
(n=308)
Placebo 
(n=285)
Age, years 67·5 (13·6) 69·6 (12·7)
Sex 
Men 187 (61%) 177 (62%)
Women 121 (39%) 108 (38%)
Ethnicity 
White 289 (94%) 270 (95%)
Asian 9 (3%) 8 (2%)
Black 3 (1%) 5 (2%)
Chinese 2 (1%) 1 (<1%)
Mixed 2 (1%) 1 (<1%)
Other 3 (1%) 0
Type of stroke
Infarction* 270 (88%) 238 (84%)
Total Anterior Circulation 98 (36%) 63 (27%)
Lacunar 58 (22%) 58 (24%)
Partial Anterior Circulation 87 (32%) 91 (38%)
Posterior Circulation 27 (10%) 25 (11%)
Missing .. 1 (<1%)
Primary haemorrhage 38 (12%) 47 (17%)
Thrombolysis received 62 (23%) 59 (25%)
Data are mean (SD) or n (%). *Oxfordshire Community Stroke Project classification. 
Table 1: Baseline demographic and clinical characteristics
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Sensitivity analyses supported the conclusions from the 
primary analysis (appendix). A per-protocol analysis could 
not be done because of the small number of patients re-
maining in the per-protocol population. Complier-average 
causal effect analyses, which used a staged definition of 
intervention compli ance, sup ported the conclusions of 
the primary analysis (appendix).
There were no apparent differences between groups in 
any of the secondary outcomes (table 2), with the exception 
of GHQ-12 at 6 months and perceived burden in 
caregivers. The co-careldopa group reported better mood 
with a 1·3 point difference in the GHQ-12 at 6 months, 
compared with the placebo group, but not at 8 weeks or 
12 months. Carers in the co-careldopa group reported 
Baseline 8 weeks 6 months 12 months
Co-careldopa 
(n=308)
Placebo 
(n=285)
Co-careldopa 
(n=271)
Placebo  
(n=261)
Co-careldopa 
(n=242)
Placebo  
(n=250)
Co-careldopa 
(n=222)
Placebo  
(n=221)
Able to walk independently 10 (3%) 7 (3%) 125/308 (41%) 127/285 (45%) 159/308 
(52%)
152/285 (53%) 159/308 
(52%)
162/285 (57%)
Odds ratio (95% CI); p value ·· ·· ·· 0·78 
(0·53–1·15); 0·212
·· ·· ·· ··
Patient-reported RMI 
(as continuous)
2·4 (2·2) 2·5 (2·2) 6·8 (4·2) 7·0 (4·2) 8·3 (4·6) 8·1 (4·5) 8·7 (4·7) 8·5 (4·6)
Adjusted mean difference 
(95% CI); p value
·· ·· ·· –0·35 
(–0·89 to 0·19); 0·198
·· 0·14 
(–0·50 to 0·79); 0·662
·· 0·17 
(–0·54 to 0·88); 0·637
NEADL* 59·0 (11·0) 58·6 (12·4) 21·0 (17·7) 20·0 (15·8) 27·2 (18·2) 27·3 (18·1) 30·4 (19·4) 29·8 (18·9)
Adjusted mean difference 
(95% CI); p value
·· ·· ·· 1·02 
(–1·27 to 3·30); 0·382
·· 0·027 
(–2·72 to 2·78); 0·985
·· 1·04 
(–1·56, 3·64); 0·434
Barthel Index 7·7 (3·8) 7·8 (3·7) 12·9 (5·1) 13·2 (4·9) 14·0 (5·1) 14·4 (5·1) 14·4 (5·4) 14·6 (5·1)
Adjusted mean difference 
(95% CI); p value
·· ·· ·· –0·22 
(-0·87 to 0·43); 0·511
·· –0·33 
(–1·08 to 0·41); 0·378
·· –0·22 
(–1·04 to 0·59); 0·591
ABILHAND, logits 0·8 (3·9) 0·3 (1·8) 0·2 (2·3) 0·4 (2·2) 0·1 (2·4) 0·3 (2·5) 0·2 (2·6) 0·4 (2·6)
Adjusted mean difference 
(95% CI); p value
·· ·· .. –0·10 
(–0·46 to 0·26); 0·585
·· –0·15 
(–0·57 to 0·27); 0·478
·· –0·16 
(–0·59 to 0·28); 0·479
GHQ-12 19·4 (6·7) 19·3 (7·0) 16·9 (7·2) 16·4 (6·6) 15·1 (7·0) 16·3 (6·8) 14·0 (6·8) 14·4 (7·2)
Adjusted mean difference 
(95% CI); p value
·· ·· .. 0·24 
(–0·88 to 1·36); 0·677
·· –1·33 
(–2·57 to 0·10); 0·035
·· –0·77 
(–2·01 to 0·52); 0·241
No sign of psychological 
distress
91 (30%) 94 (33%) 128 (42%) 121 (43%) 139 (45%) 125 (44%) 152 (49%) 133 (47%)
FAS NA NA 25·1 (7·6) 24·8 (7·4) 25·9 (8·1) 25·4 (7·6) 24·9 (8·3) 24·5 (8·2)
mRS† NA NA ·· ·· ·· ·· NA NA
0 ·· ·· 3 (1·0) 1 (0·4) 1 (0·3) 2 (0·7) ·· ··
1 ·· ·· 15 (4·9) 11 (3·9) 29 (9·4) 25 (8·8) ·· ··
2 ·· ·· 24 (7·8) 30 (10·5) 23 (7·5) 30 (10·5) ·· ··
3 ·· ·· 101 (32·8) 114 (40·0) 123 (39·9) 128 (44·9) ·· ··
4 ·· ·· 95 (30·8) 79 (27·7) 41 (13·3) 47 (16·5) ·· ··
5 ·· ·· 34 (11·0) 34 (11·9) 27 (8·8) 16 (5·6) ·· ··
6 ·· ·· 6 (1·9) 1 (0·4) 6 (1·9) 4 (1·4) ·· ··
Odds ratio (95% CI); p value ·· ·· ·· 0·87 
(0·63 to 1·21); 0·404
·· 0·81 
(0·57 to 1·14); 0·226
·· Not reported
MoCA 20·0 (6·6) 20·5 (6·0) 22·4 (6·3) 22·9 (5·5) 23·1 (6·2) 23·6 (5·5) 23·1 (5·9) 23·5 (5·6)
Adjusted mean difference 
(95% CI); p value
·· ·· ·· –0·16 
(–0·75 to 0·43); 0·592
·· –0·27 
(–0·96 to 0·42); 0·445
·· –0·19 
(–0·95 to 0·56); 0·613
Caregiver Burden Scale† NA NA 43·0 (13·4) 46·6 (13·9) 44·6 (13·6) 49·1 (14·7) 44·6 (15·1) 51·8 (15·3)
Adjusted mean difference 
(95% CI); p value
·· ·· ·· –4·55 
(0·14 to 8·96); 0·043 
·· –4·99 
(0·173 to 9·811); 0·042 
·· –7·17 
(1·70 to 12·64); 0·011 
Number of carer respondents ·· ·· 74 72 62 65 50 107
Data are mean (SD) or n (%), unless otherwise specified. The proportion of patients included for the secondary analyses are based on number of patients randomly assigned. RMI=Rivermead Mobility Index; 
a higher score indicates increasing ability to walk independently. NEADL=Nottingham Extended Activities of Daily Living Scale; a higher score indicates greater independence. ABILHAND=a Manual Ability 
Measure; raw scores are converted into a linear measure and expressed as logits; a higher number logit indicates greater patient’s perceived ability. GHQ-12=General Health Questionnaire 12; a higher score 
indicates worse health. FAS=Fatigue Assessment Scale; a higher score indicates more severe fatigue. mRS=modified Rankin Scale; a higher score indicates greater levels of current functional independence; 
patients who die are given a score of 6. MoCA=Montreal Cognitive Assessment; score <26 indicates cognitive impairment. NA=not assessed. For Bartel index, a higher score indicates greater degree of functional 
independence. *Pre-stroke score. †Higher score indicated higher burden.
Table 2: Assessments at baseline, 8 weeks, 6 months, and 12 months after randomisation
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less burden at 8 weeks (CBS mean difference –4·55 points 
[95% CI –0·14 to –8·96]; p=0·043), 6 months 
(–4·99 [–0·17 to –9·81]; p=0·042), and 12 months 
(–7·17 [–1·70 to –12·64]; p=0·011). Responses from carers 
were obtained in under half of study participants and 
numbers varied at each timepoint (table 2). During the 
12-month follow up, the proportion of participants 
reporting no psychological distress seemed to improve 
from around a third to almost half of patients in both 
placebo and co-careldopa treated groups. An increase in 
the proportion of participants who were able to walk was 
observed at 6 months in both groups. Little further change 
was observed at 12 months in either of the groups.  As 
expected, NEADL scores at 8 weeks after randomisation 
were lower than the prestroke scores in both groups 
(patients were asked their prestroke status). As for physical 
function, improvement in NEADL scores was seen at 
6 months. ABILHAND scores showed a similar pattern of 
improve ment. Good functional inde pendence (mRS score 
of 0–2) at 8 weeks was achieved in less than a fifth 
of participants in both groups. Musculo skeletal pain 
was reported by two thirds of partici pants at 8 weeks in 
both groups (appendix). 
Post-hoc subgroup analyses provided some evidence 
that partici pants with cerebral infarction might be less 
likely to recover walking ability (206 [41%] of 508 patients 
able to walk independently at 8 weeks) than those with 
intra cerebral haemorrhage (46 [54%] of 85 patients; 
table 3). There was some evidence that ability to walk 
independently at 8 weeks might be associated with higher 
baseline scores for RMI, prestroke NEADL, and Barthel 
Index. There was also weak evidence that walking at 
8 weeks could be inversely associated with age and time 
from stroke to randomisation. No evidence was found for 
an associ ation between sex and independent walking at 
8 weeks (169 [46%] of 364 men vs 83 [36%] of 229 women 
could walk independently).
132 serious adverse events were reported from 
107 (18%; table 4) participants: 74 serious adverse events in 
57 (19%) participants in the co-careldopa group and 
58 in 50 (18%) participants in the placebo group. Most of 
the serious adverse events reported in both groups were 
not suspected to be related to the trial medication (2 [3%] 
in the co-careldopa group vs 1 [2%] in the placebo group 
were suspected to be related to treatment; appendix). No 
suspected unexpected serious adverse reactions were 
reported. Slightly more deaths occurred in the co-
careldopa group the placebo group during the study 
(22 [7%] of 308 patients vs 17 [6%] of 285 patients; 
appendix). More participants in the co-careldopa group 
died within 8 weeks (6 [2%] vs 1 [0%]) but none of the 
deaths were considered likely to be related to study 
treatment. More participants in the co-careldopa group 
vomited during therapy after study drug adminis tration 
(19 [6%] vs 9 [3%]). The primary economic analysis used 
multiple imputa tion for missing data and adjustment for 
baseline EQ-5D differences. On average, patients in the 
co-careldopa group incurred higher costs and gained 
fewer QALYs than patients in the placebo group, indicat-
ing that co-careldopa is not cost-effective. Bootstrapping 
results indi cate that, at a willingness to pay threshold of 
Able to walk 
independently at 
8 weeks (n=252)
Total  
(n=593)
Estimated odds 
ratio (95% CI)
p value
Sex
Men 169 (46%) 364 (100%) 0·90 (0·60–1·35) 0·612
Women 83 (36%) 229 (100%) ·· ··
Mean age, years 65·5 (14·1) 68·5 (13·2) 0·98 (0·97–0·99) 0·010
Type of stroke
Infarction 206 (82%) 508 (86%) 0·38 (0·22–0·67) 0·001
Primary haemorrhage 46 (18%) 85 (14%) ·· ··
Mean RMI score at baseline‡ 3·1 (1·8) 2·3 (1·8) 1·52 (1·31–1·76) <0·0001
Mean Barthel Index at baseline 9·3 (3·4)* 7·7 (3·7)† 1·11 (1·03–1·19) 0·004
Pre-stroke NEADL score
Mean‡ 60·7 (10·0)‡ 58·8 (11·7)† 1·03 (1·01–1·05) 0·011
Median 66 (0–66) 63 (0–66) ·· ··
Days between stroke and randomisation
Mean 15·0 (9·6) 17·7 (10·1) 0·95 (0·93–0·97) <0·0001
Median 12 (3–59) 15 (3–59) ·· ··
Data are n (%), mean (SD), median (range). RMI=Rivermead Mobility Index. NEADL=Nottingham Extended Activities 
Daily Living. *Data missing in five patients. †Data missing from 13 patients. ‡Data missing in seven patients. ‡Data 
missing at baseline.
Table 3: Variables included in the primary analysis and estimates from stepwise multilevel logistic 
regression analysis
Co-careldopa 
(n=74)
Placebo 
(n=58)
Blood and lymphatic system disorders 1 (1%) 0 (0%)
Cardiac disorders 6 (8%) 2 (3%)
Gastrointestinal disorders 4 (5%) 3 (5%)
General disorders and administration site 
conditions
0 (0%) 1 (2%)
Hepatobiliary disorders 1 (1%) 2 (3%)
Infections and infestations 10 (14%) 6 (10%)
Injury, poisoning, and procedural 
complications
4 (5%) 3 (5%)
Metabolism and nutrition disorders 2 (3%) 1 (2%)
Musculoskeletal and connective tissue 
disorders
1 (1%) 0 (0%)
Neoplasms benign, malignant, and 
unspecified (including cysts and polyps)
2 (3%) 3 (5%)
Nervous system disorders 10 (14%) 11 (19%)
Psychiatric disorders 2 (3%) 0 (0%)
Renal and urinary disorders 2 (3%) 1 (2%)
Reproductive system and breast disorders 1 (1%) 3 (5%)
Respiratory, thoracic, and mediastinal 
disorders
8 (11%) 12 (21%)
Social circumstances 4 (5%) 0 (0%)
Vascular disorders 16 (22%) 10 (17%)
Data are n (%).
Table 4: Serious adverse events by MedDRA System Organ Classification
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£20 000 per QALY, co-careldopa has only a 7% chance of 
being cost-effective (appendix).
Discussion
The DARS study found no evidence of improvement in 
walking ability when combining dopaminergic therapy 
with motor therapy after acute stroke. Although just over 
10% patients were lost to follow-up, the findings are likely 
to be robust and generalisable to patients with limited 
mobility in the first few weeks after stroke. A greater 
proportion of patients achieved the primary outcome of 
independent walking at 8 weeks in the placebo group than 
was anticipated in comparison to a previous study 
(44% vs 26%).12 This result is most likely to be due to 
recruitment of participants at an earlier time after stroke 
onset in DARS at an average of 18 days compared with 
43 days.12 A range of secondary outcomes in DARS showed 
no suggestion of benefit on arm func tion, disability, 
activities of daily living, or cognition. Co-careldopa had an 
acceptable safety profile. Vomiting, a known side-effect of 
levodopa, was uncommon but more frequent with co-
careldopa than with placebo.
Levodopa was chosen from several other potential drug 
therapies, such as amphetamines and selective serotonin 
reuptake inhibitors (SSRIs), because levodopa has a better 
safety profile than amphetamines and was considered to 
have stronger basis for a purported mechanism of action 
on motor learning than SSRIs.23
Strengths of the trial are the double-blind, placebo-
controlled design, large participant recruitment from 
multiple NHS stroke services, and good adherence with 
study treatment and therapy sessions, with over 80% of 
participants receiving at least 20 min of motor therapy in 
over 80% of therapy sessions. Although 60% more 
placebo patients received sufficient motor therapy, fewer 
than 10% of patients met the prespecified per-protocol 
analysis criteria mainly due to participants taking the trial 
medication outside the specified 45–60 min window 
before therapy. This criterion was, in retrospect, too strict 
because serum levodopa con centration would be elevated 
at the target concentration for a wider time window of 
30–120 min. Future trials of combined timed drug and 
therapy might consider the use of less strict criteria for 
per-protocol analyses.
A limitation of the trial was the loss to follow up at 
8 weeks. The primary ITT analysis made the assumption 
that those participants with missing outcome data did not 
achieve the primary outcome (ie, walking independently). 
Sensitivity analyses testing the robustness of this assump-
tion did not alter the ITT analysis conclusion.
A possible explanation for the absence of a significant 
response to co-careldopa is the use of intermittent rather 
than sustained daily dosing, as was used in previous trials, 
including a positive small trial12 that used 3 weeks’ continu-
ous levodopa therapy. An intermittent dosing strategy was 
chosen with the intention of maximising brain dopamine 
concentrations during therapy and reducing the risk of 
adverse effects and patient with drawal. Higher doses of co-
careldopa might be bene ficial for some patients but could 
potentially lead to more adverse effects. The dose used in 
the trial produces clinical benefits in Parkinson’s disease.24 
Future phase 2 trials of recovery-enhancing drugs might 
usefully compare intermittent versus daily dosing in terms 
of tolerability and clinical measures of recovery.
Another possible hypothesis for the absence of response 
to co-careldopa is that the intensity of therapy delivered in 
DARS was insufficient. However, DARS participants 
received the 16 h recommended from a systematic review 
of augmented therapy time.25 
DARS enrolled more participants with stroke than all 
previous studies of dopaminergic therapy combined. The 
results are consistent with these smaller studies.6–12 A 
formal meta-analysis of trials of dopaminergic therapy in 
stroke recovery has not been done and, given the wide 
range of different outcome measures in populations of 
patients with stroke recruited at different times after 
stroke, might not be appropriate. Of the seven reported 
randomised trials, three showed no benefit on motor 
function,7,10,11 two showed improvements in walking speed8 
or procedural motor learning,9 and one slightly larger 
study showed a slight improvement in disability.6 One trial26 
showed that 100 mg of levodopa administered daily had a 
benefit on walking in 53 participants, with a significant 
increase in Rivermead Motor Assessment score of 
2·3 points after 3 weeks compared with placebo. This trial 
involved more frequent daily physical therapy.
Future research of pharmacotherapy and stroke re covery 
should consider incorporation of potential proof of concept 
imaging biomarkers, such as fMRI (laterality index) and 
transcranial magnetic stimulation (motor evoked poten-
tials) measures, into early phase trials.27 Future research is 
needed into the development of more sensitive clinical 
markers of motor recovery that would show proof-of-
concept efficacy on neurological impair ment in early 
phase trials before doing large pragmatic trials with activity 
and disability measures as the primary trial outcome.
DARS is the largest, multicentre, stroke rehabilitation 
trial to combine timed administration of a masked 
investigational medicinal product with therapy sessions. 
This approach required a high degree of coordination 
of drug administration with planned therapy and was 
successfully delivered with support from research teams 
from the National Institute for Health Research Stroke 
Research Network. DARS has shown that it is feasible to 
deliver multicentre trials of pharmacotherapy-enhanced 
rehabilitation in NHS stroke services but highlights the 
challenges involved in multicentre trials in deliver ing 
combined drug and motor therapy at an intensity 
recommended by expert guidelines. Although we found 
no evidence of dopaminergic therapy in conjunction with 
motor therapy improving walking after stroke, the learn-
ing and experience from DARS has lessons for the design 
and conduct of future rehabilitation multicentre trials 
investigating the effect of drugs to enhance recovery.
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